Brief: Bio-Path Announces Clearance Of IND Application For Phase 1/1B Clinical Trial Of Prexigebersen-A In Solid Tumors
27/10/2021 13:14
Oct 27 (Reuters) - Bio Path Holdings Inc BPTH.O :
* BIO-PATH HOLDINGS ANNOUNCES CLEARANCE OF INVESTIGATIONAL
NEW
DRUG APPLICATION FOR PHASE 1/1B CLINICAL TRIAL OF
PREXIGEBERSEN-A IN SOLID TUMORS
* BIO PATH HOLDINGS - EVENTUALLY, EXPECT TO HAVE SIX SITES
TO
CONDUCT PHASE 1/1B CLINICAL TRIAL
Source text for Eikon: ID:nGNX7jWlRS
Further company coverage: BPTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bio Path Holdings
See all newsBrief: Bio-Path Holdings Seeks Financing For Turnaround & Strategic Actions
Brief: Bio-Path Holdings Reports Full Year 2024 Financial Results
Brief: Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Brief: Bio-Path Provides Key Clinical Updates
Brief: Bio-Path Holdings Provides Update From Phase 1/1B Clinical Trial Of Bp1002 For Treatment Of Refractory/Relapsed Acute Myeloid Leukemia